Servus Credit Union reported record year-to-date profitability, delivering one of the strongest financial performances in the Canadian credit union sector.
Originally published via Source Article.
Category: News
News
-
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), today announced its licensee – Unbuzzd Wellness Inc. (the “Company” or “Unbuzzd“), the company behind unbuzzd™ (“unbuzzd”) — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Michael Zapolin (“Zappy”) as CEO. This marks a pivotal milestone in the Company. His mandate includes financing and listing Unbuzzd on a stock exchange and then executing a nationwide commercial marketing and product rollout in the United States.
Originally published via Source Article.
-
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), today announced its licensee – Unbuzzd Wellness Inc. (the “Company” or “Unbuzzd“), the company behind unbuzzd™ (“unbuzzd”) — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Michael Zapolin (“Zappy”) as CEO. This marks a pivotal milestone in the Company. His mandate includes financing and listing Unbuzzd on a stock exchange and then executing a nationwide commercial marketing and product rollout in the United States.
Originally published via Source Article.
-
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), today announced its licensee – Unbuzzd Wellness Inc. (the “Company” or “Unbuzzd“), the company behind unbuzzd™ (“unbuzzd”) — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Michael Zapolin (“Zappy”) as CEO. This marks a pivotal milestone in the Company. His mandate includes financing and listing Unbuzzd on a stock exchange and then executing a nationwide commercial marketing and product rollout in the United States.
Originally published via Source Article.
-
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil
Originally published via Source Article.
-
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil
Originally published via Source Article.
-
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil
Originally published via Source Article.
-
Cronos Hosts 2026 Investor Day
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos Growing Company Inc. Kingsville location.
Presentation materials can be accessed on the Company’s Investor Relations website under Events & Presentations at: https://ir.thecronosgroup.com/events-presentationsOriginally published via Source Article.
-
Cronos Hosts 2026 Investor Day
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos Growing Company Inc. Kingsville location.
Presentation materials can be accessed on the Company’s Investor Relations website under Events & Presentations at: https://ir.thecronosgroup.com/events-presentationsOriginally published via Source Article.
-
Cronos Hosts 2026 Investor Day
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos Growing Company Inc. Kingsville location.
Presentation materials can be accessed on the Company’s Investor Relations website under Events & Presentations at: https://ir.thecronosgroup.com/events-presentationsOriginally published via Source Article.